Harrow (NASDAQ: HROW) shares climbed after the company announced the relaunch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, an FDA-approved treatment for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease that primarily affects children. The move reinforces Harrow’s strategy of expanding its ophthalmology portfolio through differentiated therapies, while improving access to treatments that address underserved areas of eye care.

Key Highlights

  • Harrow relaunched VERKAZIA, an FDA-approved steroid-sparing treatment for vernal keratoconjunctivitis.
  • The company is implementing physician education, affordability, and patient-access programs to support adoption.
  • VKC remains an underdiagnosed chronic pediatric eye disease with limited long-term treatment options.
  • VERKAZIA targets underlying inflammation and may reduce reliance on corticosteroid therapies.
  • Investors reacted positively to the product relaunch, viewing it as a potential contributor to Harrow’s long-term ophthalmology growth strategy.

Harrow Shares Gain Following VERKAZIA Relaunch

Harrow (NASDAQ: HROW) shares rose nearly 10% after the company announced the relaunch of VERKAZIA, a prescription cyclosporine ophthalmic emulsion indicated for all forms of vernal keratoconjunctivitis. The stock has gained more than 20% over the past month, reflecting growing investor interest in the company's expanding ophthalmic product portfolio.

Management stated that the relaunch is focused on ensuring consistent product availability, improving patient access, and reducing barriers to treatment. Chief Executive Officer Mark Baum described VERKAZIA as one of the company’s strategic priority products and emphasized efforts to establish dependable supply and broader physician adoption.

VERKAZIA Addresses an Underserved Pediatric Eye Disease Market

Vernal keratoconjunctivitis is a chronic inflammatory eye disorder that primarily affects children and adolescents. The condition can cause severe itching, light sensitivity, tearing, pain, and corneal damage, potentially leading to long-term vision complications if inadequately treated.

Historically, treatment options have been limited. While antihistamines are commonly prescribed, many patients remain inadequately controlled and may require corticosteroids for symptom management. However, long-term steroid use carries well-documented risks, including glaucoma and cataract formation.

VERKAZIA functions as a calcineurin inhibitor immunomodulator, targeting the inflammatory pathways underlying the disease rather than only addressing symptoms. This mechanism provides clinicians with a steroid-sparing option for long-term disease management, an important consideration in pediatric populations.

Clinical Profile Supports Long-Term Adoption Potential

According to Harrow, randomized clinical studies demonstrated that VERKAZIA improved corneal damage associated with VKC, reduced symptoms such as itching and photophobia, and lowered the need for corticosteroid rescue therapy compared with control treatments.

The therapy's safety profile may support broader use among children requiring extended treatment durations. Increasing clinical emphasis on early intervention and disease-modifying therapies has also expanded interest in calcineurin inhibitors for chronic ocular inflammatory diseases.

The company is backing the relaunch with physician education initiatives and affordability programs designed to improve treatment uptake and continuity of care.

Growth Strategy Extends Beyond a Single Product

Investor optimism also reflects Harrow’s broader commercial strategy. Management has previously outlined expectations for continued revenue and EBITDA expansion through 2028, supported by new product launches, ophthalmic biosimilars, sales-force expansion, and increasing market penetration across its portfolio.

VERKAZIA represents the second of three priority products identified by management for focused commercial execution. The relaunch therefore signals not only a product-specific opportunity but also progress in the company's broader ophthalmology growth plan.

Why Investors Are Reacting Positively

Harrow’s stock is rising because investors view the VERKAZIA relaunch as a catalyst that strengthens the company’s position in a specialized ophthalmology market with significant unmet medical need. The combination of an FDA-approved therapy, a chronic pediatric patient population, expanding physician awareness, and enhanced access initiatives creates a potential pathway for increased prescription adoption.

While commercial execution remains important, the announcement highlights Harrow’s strategy of building differentiated ophthalmic franchises around therapies that address underserved conditions and reduce dependence on legacy treatment approaches.